Shots:

•  Alcon is removing CyPass globally revealing its unmet needs with safety of patients with the guidance for surgeons to stop its further use and return the fresh devices
•  The above decision is on the basis of five-year data from COMPASS-XT long-term safety study
• The study showed reduction in intraocular pressure at two yrs- resulting a little difference in endothelial cell loss and at five yrs experienced reduction in endothelial cell loss vs cataract surgery alone
• Sukamenak

Ref: Novartis | Image:  Novartis